TREATMENT OPTIONS IN ONCOLOGY:@0.084848:0.038601:0.493541:0.038601:0.493541:0.019343:0.084848:0.019343:0.010019:0.014276:0.012606:0.015487:0.010019:0.021613:0.012606:0.017404:0.010019:0.006515:0.020438:0.013923:0.010019:0.005315:0.020438:0.017404:0.011712:0.006515:0.005315:0.017404:0.006515:0.020438:0.017404:0.019121:0.020438:0.010866:0.020438:0.020508:0.013923
16:@0.023705:0.038809:0.044778:0.038809:0.044778:0.019212:0.023705:0.019212:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.084848:0.970015:0.320957:0.970015:0.320957:0.956010:0.084848:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
52.  Dhanasekaran R,  Kwo  PY.  The liver in On-:@0.084848:0.094740:0.475784:0.094740:0.475784:0.080735:0.084848:0.080735:0.009476:0.009476:0.004738:0.012657:0.000000:0.012726:0.010434:0.011682:0.010434:0.011682:0.006636:0.011118:0.008586:0.011682:0.005148:0.011682:0.010434:0.007372:0.010382:0.004738:0.004738:0.002624:0.010109:0.014214:0.011203:0.004738:0.002622:0.010126:0.009009:0.004738:0.004738:0.002626:0.007286:0.010434:0.011118:0.007372:0.003421:0.003421:0.009476:0.011118:0.005148:0.007372:0.003421:0.010434:0.007372:0.014864:0.010434:0.005679
cology. :@0.121195:0.108886:0.188244:0.108886:0.188244:0.094881:0.121195:0.094881:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168:0.004738:0.004738
Clin Liver  Dis:@0.198438:0.108886:0.319349:0.108886:0.319349:0.094881:0.198438:0.094881:0.013906:0.003421:0.003421:0.010434:0.014949:0.007902:0.003421:0.009476:0.011118:0.005148:0.004738:0.010194:0.012726:0.003421:0.006636
.  2017 Nov;21(4): :@0.319366:0.108886:0.480506:0.108886:0.480506:0.094881:0.319366:0.094881:0.004738:0.004738:0.010199:0.009476:0.009476:0.009476:0.009476:0.014949:0.012657:0.011203:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004750:0.004738
697-707.:@0.121212:0.123033:0.188484:0.123033:0.188484:0.109027:0.121212:0.109027:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
53.  Knijnenburg  SL,  Mulder  RL,  Schouten-Van :@0.084865:0.137179:0.480506:0.137179:0.480506:0.123174:0.084865:0.123174:0.009476:0.009476:0.004738:0.012657:0.000000:0.010109:0.010434:0.003421:0.003472:0.010434:0.011118:0.010434:0.011665:0.010399:0.005148:0.011511:0.004738:0.004695:0.008518:0.007902:0.004738:0.004738:0.004693:0.015719:0.010399:0.003421:0.011716:0.011118:0.005148:0.004738:0.004693:0.010382:0.007902:0.004738:0.004738:0.004692:0.008518:0.011067:0.010434:0.011203:0.010399:0.005798:0.011118:0.010434:0.005679:0.010218:0.011682:0.010434:0.004738
Meeteren  AY, :@0.121212:0.151325:0.240684:0.151325:0.240684:0.137320:0.121212:0.137320:0.015719:0.011118:0.011118:0.005798:0.011118:0.005070:0.011118:0.010434:0.004738:0.004741:0.010564:0.008462:0.004738:0.004738
et  al:@0.245424:0.151325:0.286926:0.151325:0.286926:0.137320:0.245424:0.137320:0.011118:0.005798:0.004738:0.004745:0.011682:0.003421
.  Early and  late  renal :@0.286926:0.151325:0.480510:0.151325:0.480510:0.137320:0.286926:0.137320:0.004738:0.004738:0.004741:0.009168:0.011682:0.005148:0.003421:0.009168:0.009493:0.011682:0.010434:0.011716:0.004738:0.004745:0.003421:0.011682:0.005798:0.011118:0.004738:0.004743:0.005078:0.011118:0.010434:0.011682:0.003421:0.004738
adverse effects after potentially nephro-:@0.121212:0.165472:0.475758:0.165472:0.475758:0.151466:0.121212:0.151466:0.011682:0.011716:0.009476:0.011118:0.005148:0.006636:0.011118:0.009818:0.011118:0.005419:0.005371:0.011118:0.011067:0.005798:0.006636:0.009818:0.011682:0.005371:0.005798:0.011118:0.005148:0.009818:0.011665:0.011203:0.005798:0.011118:0.010434:0.005798:0.003421:0.011682:0.003421:0.003421:0.009168:0.009818:0.010434:0.011118:0.011665:0.010434:0.005073:0.011203:0.005679
toxic  treatment for  childhood cancer. :@0.121212:0.179618:0.480537:0.179618:0.480537:0.165613:0.121212:0.165613:0.005798:0.011203:0.008210:0.003421:0.011067:0.004738:0.010682:0.005798:0.005075:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.015428:0.005371:0.011203:0.005148:0.004738:0.010677:0.011067:0.010434:0.003421:0.003421:0.011716:0.010434:0.011203:0.011203:0.011716:0.015428:0.011067:0.011682:0.010434:0.011067:0.011118:0.003890:0.004738:0.004738
Cochrane  Database Syst Rev:@0.121212:0.193765:0.380956:0.193765:0.380956:0.179759:0.121212:0.179759:0.013906:0.011203:0.011067:0.010434:0.005148:0.011682:0.010434:0.011118:0.004738:0.005470:0.012726:0.011682:0.005798:0.011682:0.011665:0.011682:0.006636:0.011118:0.010228:0.008518:0.009168:0.006636:0.005798:0.010228:0.010382:0.011118:0.009476
.  2013 Oct :@0.380956:0.193765:0.480510:0.193765:0.480510:0.179759:0.380956:0.179759:0.004738:0.004738:0.005480:0.009476:0.009476:0.009476:0.009476:0.010228:0.014864:0.011067:0.005798:0.004738
8;(10):CD008944.:@0.121212:0.207911:0.259963:0.207911:0.259963:0.193906:0.121212:0.193906:0.009476:0.004738:0.006312:0.009476:0.009476:0.006312:0.004738:0.013906:0.012726:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.004738
54.  Manohar S, Leung N. Cisplatin nephrotox-:@0.084865:0.222057:0.475768:0.222057:0.475768:0.208052:0.084865:0.208052:0.009476:0.009476:0.004738:0.012657:0.000000:0.015719:0.011682:0.010434:0.011203:0.010434:0.011682:0.005148:0.007004:0.008518:0.004738:0.007013:0.007902:0.011118:0.010399:0.010434:0.011511:0.007004:0.012657:0.004738:0.007013:0.013906:0.003421:0.006636:0.011665:0.003421:0.011682:0.005810:0.003421:0.010434:0.007013:0.010434:0.011118:0.011665:0.010434:0.005073:0.011203:0.005798:0.011203:0.008188:0.005679
icity: a review of the literature. :@0.121212:0.236204:0.387464:0.236204:0.387464:0.222198:0.121212:0.222198:0.003421:0.011067:0.003421:0.005798:0.009168:0.004738:0.007235:0.011682:0.007235:0.005078:0.011118:0.009476:0.003421:0.011118:0.014214:0.007235:0.011203:0.005371:0.007227:0.005798:0.010434:0.011118:0.007221:0.003421:0.003421:0.005798:0.011118:0.005148:0.011682:0.005798:0.010399:0.005075:0.011118:0.004738:0.004738
J Nephrol. :@0.389939:0.236204:0.480541:0.236204:0.480541:0.222198:0.389939:0.222198:0.008244:0.007235:0.012657:0.011118:0.011665:0.010434:0.005148:0.011203:0.003421:0.004738:0.004738
2018 Feb;31(1):15-25 .:@0.121212:0.250350:0.298516:0.250350:0.298516:0.236345:0.121212:0.236345:0.009476:0.009476:0.009476:0.009476:0.004738:0.008296:0.011118:0.011665:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738:0.004738
55.  Chovanec  M,  Abu  Zaid M,  Hanna N, :@0.084865:0.264496:0.454415:0.264496:0.454415:0.250491:0.084865:0.250491:0.009476:0.009476:0.004738:0.012657:0.000000:0.013906:0.010434:0.011203:0.009476:0.011682:0.010434:0.011118:0.011067:0.004738:0.004452:0.015719:0.004738:0.004738:0.004456:0.012657:0.011665:0.010399:0.004738:0.004454:0.008210:0.011682:0.003421:0.011716:0.009202:0.015719:0.004738:0.004738:0.004454:0.011682:0.011682:0.010434:0.010434:0.011682:0.009202:0.012657:0.004738:0.004738
et :@0.458869:0.264496:0.480523:0.264496:0.480523:0.250491:0.458869:0.250491:0.011118:0.005798:0.004738
al:@0.121212:0.278643:0.136315:0.278643:0.136315:0.264638:0.121212:0.264638:0.011682:0.003421
. Long-term toxicity of cisplatin in germ-:@0.136315:0.278643:0.475779:0.278643:0.475779:0.264638:0.136315:0.264638:0.004738:0.007235:0.007902:0.011203:0.010434:0.011511:0.005679:0.005798:0.011118:0.005607:0.016044:0.007235:0.005798:0.011203:0.008210:0.003421:0.011067:0.003421:0.005798:0.009168:0.007235:0.011203:0.005371:0.007227:0.011067:0.003421:0.006636:0.011665:0.003421:0.011682:0.005798:0.003421:0.010434:0.007235:0.003421:0.010434:0.007235:0.011511:0.011118:0.005615:0.016044:0.005679
cell tumor  survivors. :@0.121212:0.292789:0.290576:0.292789:0.290576:0.278784:0.121212:0.278784:0.011067:0.011118:0.003421:0.003421:0.007372:0.005798:0.010399:0.016044:0.011203:0.005148:0.004738:0.002614:0.006636:0.010399:0.005148:0.009476:0.003421:0.009476:0.011203:0.005148:0.006636:0.004738:0.004738
Ann  Oncol:@0.293210:0.292789:0.385076:0.292789:0.385076:0.278784:0.293210:0.278784:0.012657:0.010434:0.010434:0.004738:0.002615:0.014864:0.010434:0.011067:0.011203:0.003421
.  2017 Nov :@0.385076:0.292789:0.480523:0.292789:0.480523:0.278784:0.385076:0.278784:0.004738:0.004738:0.002622:0.009476:0.009476:0.009476:0.009476:0.007372:0.012657:0.011203:0.009476:0.004738
1;28(11):2670-2679.:@0.121212:0.306936:0.276913:0.306936:0.276913:0.292930:0.121212:0.292930:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738
56.  Waissbluth S, Peleva E, Daniel SJ. Platinum-:@0.084865:0.321082:0.475762:0.321082:0.475762:0.307077:0.084865:0.307077:0.009476:0.009476:0.004738:0.012657:0.000000:0.015568:0.011682:0.003421:0.006636:0.006636:0.011665:0.003421:0.010399:0.005798:0.010434:0.005590:0.008518:0.004738:0.005576:0.010126:0.011118:0.003421:0.011118:0.009476:0.011682:0.005576:0.009168:0.004738:0.005576:0.012726:0.011682:0.010434:0.003421:0.011118:0.003421:0.005586:0.008518:0.008244:0.004738:0.005576:0.010126:0.003421:0.011682:0.005798:0.003421:0.010434:0.010399:0.016044:0.005679
induced ototoxicity: a review of prevailing :@0.121212:0.335228:0.480505:0.335228:0.480505:0.321223:0.121212:0.321223:0.003421:0.010434:0.011716:0.010399:0.011067:0.011118:0.011716:0.005952:0.011203:0.005798:0.011203:0.005798:0.011203:0.008210:0.003421:0.011053:0.003421:0.005798:0.009168:0.004738:0.005952:0.011682:0.005952:0.005078:0.011118:0.009476:0.003421:0.011118:0.014214:0.005952:0.011203:0.005371:0.005952:0.011665:0.005077:0.011118:0.009476:0.011682:0.003421:0.003421:0.003421:0.010434:0.011511:0.004738
ototoxicity criteria. :@0.121212:0.349375:0.279958:0.349375:0.279958:0.335369:0.121212:0.335369:0.011203:0.005798:0.011203:0.005798:0.011203:0.008210:0.003421:0.011067:0.003421:0.005798:0.009168:0.006175:0.011067:0.005148:0.003421:0.005798:0.011118:0.005148:0.003421:0.011682:0.004738:0.004738
Eur Arch Otorhinolaryn-:@0.281395:0.349375:0.475786:0.349375:0.475786:0.335369:0.281395:0.335369:0.009168:0.010399:0.005148:0.006175:0.012657:0.005148:0.011067:0.010434:0.006166:0.014864:0.005798:0.011203:0.005148:0.010425:0.003421:0.010434:0.011203:0.003421:0.011682:0.005148:0.009168:0.010434:0.005679
gol:@0.121212:0.363521:0.147348:0.363521:0.147348:0.349516:0.121212:0.349516:0.011511:0.011203:0.003421
. 2017 Mar;274(3):1187-1196.:@0.147348:0.363521:0.378239:0.363521:0.378239:0.349516:0.147348:0.349516:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.015719:0.011682:0.005148:0.004738:0.009476:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738
57.  Den:@0.084865:0.377668:0.155489:0.377668:0.155489:0.363662:0.084865:0.363662:0.009476:0.009476:0.004738:0.012657:0.000000:0.012726:0.011118:0.010434
Hollander:@0.179846:0.377668:0.259672:0.377668:0.259672:0.363662:0.179846:0.363662:0.011682:0.011203:0.003421:0.003421:0.011682:0.010434:0.011716:0.011118:0.005148
MW,:@0.284029:0.377668:0.319091:0.377668:0.319091:0.363662:0.284029:0.363662:0.015719:0.014605:0.004738
Westerink:@0.343447:0.377668:0.421325:0.377668:0.421325:0.363662:0.343447:0.363662:0.015618:0.011118:0.006636:0.005798:0.011118:0.005148:0.003421:0.010434:0.008586
ND, :@0.445672:0.377668:0.480506:0.377668:0.480506:0.363662:0.445672:0.363662:0.012657:0.012726:0.004714:0.004738
Lubberts S, :@0.121212:0.391814:0.217903:0.391814:0.217903:0.377809:0.121212:0.377809:0.007902:0.010399:0.011665:0.011665:0.011118:0.005148:0.005798:0.006636:0.008364:0.008518:0.004738:0.004738
et al:@0.221529:0.391814:0.261913:0.391814:0.261913:0.377809:0.221529:0.377809:0.011118:0.005798:0.008364:0.011682:0.003421
. Bleomycin-induced pul-:@0.261913:0.391814:0.475786:0.391814:0.475786:0.377809:0.261913:0.377809:0.004738:0.008364:0.009818:0.003421:0.011118:0.011203:0.016044:0.009168:0.011067:0.003421:0.010434:0.005679:0.003421:0.010434:0.011716:0.010399:0.011067:0.011118:0.011716:0.008364:0.011665:0.010399:0.003421:0.005679
monary changes on restaging computed :@0.121212:0.405960:0.480522:0.405960:0.480522:0.391955:0.121212:0.391955:0.016044:0.011203:0.010434:0.011682:0.005148:0.009168:0.007543:0.011067:0.010434:0.011682:0.010434:0.011511:0.011118:0.006636:0.007543:0.011203:0.010434:0.007543:0.005078:0.011118:0.006636:0.005798:0.011682:0.011511:0.003421:0.010434:0.011511:0.007543:0.011067:0.011203:0.016044:0.011665:0.010399:0.005798:0.011118:0.011716:0.004738
tomography  scans in  two  thirds of  tes-:@0.121212:0.420107:0.475787:0.420107:0.475787:0.406101:0.121212:0.406101:0.005798:0.011203:0.016044:0.011203:0.011511:0.005148:0.011682:0.011665:0.010434:0.009168:0.004738:0.006972:0.006636:0.011067:0.011682:0.010434:0.006636:0.011734:0.003421:0.010434:0.004738:0.006985:0.005798:0.014214:0.011203:0.004738:0.006980:0.005798:0.010434:0.003421:0.005044:0.011716:0.006636:0.011734:0.011203:0.005371:0.004738:0.006980:0.005798:0.011118:0.006636:0.005679
ticular cancer  patients show no correla-:@0.121212:0.434253:0.475784:0.434253:0.475784:0.420248:0.121212:0.420248:0.005798:0.003421:0.011067:0.010399:0.003421:0.011682:0.005148:0.009613:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.004866:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.009613:0.006636:0.010434:0.011203:0.014214:0.009613:0.010434:0.011203:0.009613:0.011067:0.011203:0.005148:0.005070:0.011118:0.003421:0.011682:0.005679
tion with fibrosis markers. :@0.121212:0.448399:0.334084:0.448399:0.334084:0.434394:0.121212:0.434394:0.005798:0.003421:0.011203:0.010434:0.007109:0.014214:0.003421:0.005798:0.010434:0.007114:0.004165:0.004165:0.011665:0.005077:0.011203:0.006636:0.003421:0.006636:0.007119:0.016044:0.011682:0.005148:0.008586:0.011118:0.005148:0.006636:0.004738:0.004738
Oncologist.:@0.336453:0.448399:0.430750:0.448399:0.430750:0.434394:0.336453:0.434394:0.014864:0.010434:0.011067:0.011203:0.003421:0.011203:0.011511:0.003421:0.006636:0.005798:0.004738
 2016 :@0.430750:0.448399:0.480506:0.448399:0.480506:0.434394:0.430750:0.434394:0.007115:0.009476:0.009476:0.009476:0.009476:0.004738
Aug;21(8):995-1001.:@0.121212:0.462546:0.283054:0.462546:0.283054:0.448541:0.121212:0.448541:0.012657:0.010399:0.011511:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738
58.  Baselga J, Zamagni C, Gómez P, :@0.084865:0.476692:0.387554:0.476692:0.387554:0.462687:0.084865:0.462687:0.009476:0.009476:0.004738:0.012657:0.000000:0.009818:0.011682:0.006636:0.011118:0.003421:0.011511:0.011682:0.003575:0.008244:0.004738:0.003559:0.008210:0.011682:0.016044:0.011682:0.011511:0.010434:0.003421:0.003565:0.013906:0.004738:0.003561:0.014915:0.011203:0.016044:0.011118:0.007269:0.003561:0.008017:0.004738:0.004738
et al:@0.386381:0.476692:0.421960:0.476692:0.421960:0.462687:0.386381:0.462687:0.011118:0.005798:0.003559:0.011682:0.003421
. RESIL-:@0.421960:0.476692:0.475774:0.476692:0.475774:0.462687:0.421960:0.462687:0.004738:0.003561:0.010382:0.009168:0.008518:0.003866:0.007902:0.005679
IENCE: Phase III randomized, double-blind :@0.121212:0.490839:0.480523:0.490839:0.480523:0.476833:0.121212:0.476833:0.003866:0.009168:0.012657:0.013906:0.009168:0.004738:0.007286:0.010126:0.010434:0.011682:0.006636:0.011118:0.007286:0.003866:0.003866:0.003866:0.007286:0.005148:0.011682:0.010434:0.011716:0.011203:0.016044:0.003421:0.007269:0.011118:0.011716:0.004738:0.007269:0.011716:0.011203:0.010399:0.011665:0.003421:0.011118:0.005679:0.011665:0.003421:0.003421:0.010434:0.011716:0.004738
trial comparing sorafenib  with capecit-:@0.121212:0.504985:0.475794:0.504985:0.475794:0.490980:0.121212:0.490980:0.005798:0.005148:0.003421:0.011682:0.003421:0.012726:0.011067:0.011203:0.016044:0.011665:0.011682:0.005148:0.003421:0.010434:0.011511:0.012726:0.006636:0.011203:0.005148:0.011682:0.005371:0.011118:0.010434:0.003421:0.011665:0.004738:0.007979:0.014214:0.003421:0.005798:0.010434:0.012726:0.011067:0.011682:0.011665:0.011118:0.011067:0.003421:0.005798:0.005679
abine versus placebo with capecitabine in :@0.121212:0.519131:0.480510:0.519131:0.480510:0.505126:0.121212:0.505126:0.011682:0.011665:0.003421:0.010434:0.011118:0.004635:0.009476:0.011118:0.005148:0.006636:0.010399:0.006636:0.004627:0.011665:0.003421:0.011682:0.011067:0.011118:0.011665:0.011203:0.004623:0.014214:0.003421:0.005798:0.010434:0.004625:0.011067:0.011682:0.011665:0.011118:0.011067:0.003421:0.005798:0.011682:0.011665:0.003421:0.010434:0.011118:0.004635:0.003421:0.010434:0.004738
locally advanced or metastatic HER2-neg-:@0.121212:0.533278:0.475760:0.533278:0.475760:0.519273:0.121212:0.519273:0.003421:0.011203:0.011067:0.011682:0.003421:0.003421:0.009168:0.005439:0.011682:0.011716:0.009476:0.011682:0.010434:0.011067:0.011118:0.011716:0.005439:0.011203:0.005148:0.005431:0.016044:0.011118:0.005798:0.011682:0.006636:0.005798:0.011682:0.005798:0.003421:0.011067:0.005439:0.011682:0.009168:0.010382:0.009476:0.005679:0.010434:0.011118:0.011511:0.005679
ative breast cancer. :@0.121212:0.547424:0.302474:0.547424:0.302474:0.533419:0.121212:0.533419:0.011682:0.005798:0.003421:0.009476:0.011118:0.009527:0.011665:0.005080:0.011118:0.011682:0.006636:0.005798:0.009527:0.011067:0.011682:0.010434:0.011067:0.011118:0.003890:0.004738:0.004738
Clin Breast Cancer.:@0.307263:0.547424:0.475792:0.547424:0.475792:0.533419:0.307263:0.533419:0.013906:0.003421:0.003421:0.010434:0.009527:0.009818:0.005148:0.011118:0.011682:0.006636:0.005798:0.009527:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738
 :@0.475768:0.547424:0.480506:0.547424:0.480506:0.533419:0.475768:0.533419:0.004738
2017 Dec;17(8):585-594.e4.:@0.121212:0.561571:0.341893:0.561571:0.341893:0.547565:0.121212:0.547565:0.009476:0.009476:0.009476:0.009476:0.004738:0.012726:0.011118:0.011067:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738:0.011118:0.009476:0.004738
59.  Baselga J,  Costa  F,  Gomez H, :@0.084865:0.575717:0.397675:0.575717:0.397675:0.561712:0.084865:0.561712:0.009476:0.009476:0.004738:0.012657:0.000000:0.009818:0.011682:0.006636:0.011118:0.003421:0.011511:0.011682:0.011152:0.008244:0.004738:0.004738:0.006406:0.013906:0.011203:0.006636:0.005798:0.011682:0.004738:0.006406:0.006205:0.004738:0.004738:0.006406:0.014915:0.011203:0.016044:0.011118:0.007269:0.011152:0.011682:0.004738:0.004738
et  al:@0.404089:0.575717:0.447250:0.575717:0.447250:0.561712:0.404089:0.561712:0.011118:0.005798:0.004738:0.006404:0.011682:0.003421
.  A :@0.447250:0.575717:0.480527:0.575717:0.480527:0.561712:0.447250:0.561712:0.004738:0.004738:0.006406:0.012657:0.004738
phase 3 trial comparing capecitabin E in :@0.121212:0.589863:0.480523:0.589863:0.480523:0.575858:0.121212:0.575858:0.011665:0.010434:0.011682:0.006636:0.011118:0.007646:0.009476:0.007646:0.005798:0.005148:0.003421:0.011682:0.003421:0.007646:0.011067:0.011203:0.016044:0.011665:0.011682:0.005148:0.003421:0.010434:0.011511:0.007646:0.011067:0.011682:0.011665:0.011118:0.011067:0.003421:0.005798:0.011682:0.011665:0.003421:0.010434:0.007646:0.009168:0.007646:0.003421:0.010434:0.004738
combination  with  Sorafen  Ib or  placebo :@0.560606:0.094893:0.919909:0.094893:0.919909:0.080887:0.560606:0.080887:0.011067:0.011203:0.016044:0.011665:0.003421:0.010434:0.011682:0.005798:0.003421:0.011203:0.010434:0.004738:0.004690:0.014214:0.003421:0.005798:0.010434:0.004738:0.004693:0.008518:0.011203:0.005148:0.011682:0.005371:0.011118:0.010434:0.004738:0.004685:0.003866:0.011665:0.009442:0.011203:0.005148:0.004738:0.004687:0.011665:0.003421:0.011682:0.011067:0.011118:0.011665:0.011203:0.004738
for treatment of locally advanced or meta-:@0.560606:0.109039:0.915176:0.109039:0.915176:0.095034:0.560606:0.095034:0.005371:0.011203:0.005148:0.004069:0.005798:0.005077:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.004069:0.011203:0.005371:0.004074:0.003421:0.011203:0.011067:0.011682:0.003421:0.003421:0.009168:0.004088:0.011682:0.011716:0.009476:0.011682:0.010434:0.011067:0.011118:0.011716:0.004088:0.011203:0.005148:0.004071:0.016044:0.011118:0.005798:0.011682:0.005679
statIc HER2-Negative breast Cancer  (the :@0.560606:0.123185:0.919909:0.123185:0.919909:0.109180:0.560606:0.109180:0.006636:0.005798:0.011682:0.005798:0.003866:0.011067:0.009390:0.011682:0.009168:0.010382:0.009476:0.005679:0.012657:0.011118:0.011511:0.011682:0.005798:0.003421:0.009476:0.011118:0.009390:0.011665:0.005082:0.011118:0.011682:0.006636:0.005798:0.009390:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.004642:0.006312:0.005798:0.010434:0.011118:0.004738
RESILIENCE study): study protocol  for  a :@0.560606:0.137332:0.919907:0.137332:0.919907:0.123327:0.560606:0.123327:0.010382:0.009168:0.008518:0.003866:0.007902:0.003866:0.009168:0.012657:0.013906:0.009168:0.012691:0.006636:0.005798:0.010399:0.011716:0.009168:0.006312:0.004738:0.012691:0.006636:0.005798:0.010399:0.011716:0.009168:0.012691:0.011665:0.005080:0.011203:0.005798:0.011203:0.011067:0.011203:0.003421:0.004738:0.007938:0.005371:0.011203:0.005148:0.004738:0.007942:0.011682:0.004738
randomized controlled trial. :@0.560606:0.151478:0.797289:0.151478:0.797289:0.137473:0.560606:0.137473:0.005148:0.011682:0.010434:0.011716:0.011203:0.016044:0.003421:0.007269:0.011118:0.011716:0.006760:0.011067:0.011203:0.010434:0.005798:0.005070:0.011203:0.003421:0.003421:0.011118:0.011716:0.006773:0.005798:0.005148:0.003421:0.011682:0.003421:0.004738:0.004738
Trials. :@0.799325:0.151478:0.846396:0.151478:0.846396:0.137473:0.799325:0.137473:0.007286:0.005148:0.003421:0.011682:0.003421:0.006636:0.004738:0.004738
2013 Jul :@0.848421:0.151478:0.919900:0.151478:0.919900:0.137473:0.848421:0.137473:0.009476:0.009476:0.009476:0.009476:0.006773:0.008244:0.010399:0.003421:0.004738
22;14:228.:@0.560606:0.165625:0.641151:0.165625:0.641151:0.151619:0.560606:0.151619:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738
60.  Randrup  HC,  Grimm D, Bauer  J, :@0.524259:0.179771:0.839821:0.179771:0.839821:0.165766:0.524259:0.165766:0.009476:0.009476:0.004738:0.012657:0.000000:0.010382:0.011682:0.010434:0.011716:0.005148:0.010399:0.011665:0.004738:0.002966:0.011682:0.013906:0.004738:0.004738:0.002968:0.014915:0.005148:0.003421:0.016044:0.016044:0.007714:0.012726:0.004738:0.007714:0.009818:0.011682:0.010399:0.011118:0.005148:0.004738:0.002964:0.008244:0.004738:0.004738
et  al. :@0.842777:0.179771:0.891976:0.179771:0.891976:0.165766:0.842777:0.165766:0.011118:0.005798:0.004738:0.002966:0.011682:0.003421:0.004738:0.004738
Ef-:@0.894952:0.179771:0.915169:0.179771:0.915169:0.165766:0.894952:0.165766:0.009168:0.005371:0.005679
fects  and  side effects  of  using  sorafenib :@0.560606:0.193917:0.919900:0.193917:0.919900:0.179912:0.560606:0.179912:0.005371:0.011118:0.011067:0.005798:0.006636:0.004738:0.004538:0.011682:0.010434:0.011716:0.004738:0.004541:0.006636:0.003421:0.011716:0.011118:0.009288:0.011118:0.005420:0.005371:0.011118:0.011067:0.005798:0.006636:0.004738:0.004538:0.011203:0.005371:0.004738:0.004536:0.010399:0.006636:0.003421:0.010434:0.011511:0.004738:0.004529:0.006636:0.011203:0.005148:0.011682:0.005371:0.011118:0.010434:0.003421:0.011665:0.004738
and sunitinib in the treatment of metastatic :@0.560606:0.208064:0.919924:0.208064:0.919924:0.194058:0.560606:0.194058:0.011682:0.010434:0.011716:0.004242:0.006636:0.010399:0.010434:0.003421:0.005798:0.003421:0.010434:0.003421:0.011665:0.004242:0.003421:0.010434:0.004242:0.005798:0.010434:0.011118:0.004242:0.005798:0.005077:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.004228:0.011203:0.005371:0.004232:0.016044:0.011118:0.005798:0.011682:0.006636:0.005798:0.011682:0.005798:0.003421:0.011067:0.004738
renal cell carcinoma. :@0.560606:0.222210:0.740474:0.222210:0.740474:0.208205:0.560606:0.208205:0.005078:0.011118:0.010434:0.011682:0.003421:0.004002:0.011067:0.011118:0.003421:0.003421:0.004002:0.011067:0.011682:0.005029:0.011067:0.003421:0.010434:0.011203:0.016044:0.011682:0.004738:0.004738
Int J Mol Sci. :@0.739738:0.222210:0.842912:0.222210:0.842912:0.208205:0.739738:0.208205:0.003866:0.010434:0.005798:0.004002:0.008244:0.004002:0.015719:0.011203:0.003421:0.004002:0.008518:0.011067:0.003421:0.004738:0.004738
2017 Feb :@0.842176:0.222210:0.919912:0.222210:0.919912:0.208205:0.842176:0.208205:0.009476:0.009476:0.009476:0.009476:0.004016:0.008296:0.011118:0.011665:0.004738
21;18(2):ii: E461.:@0.560606:0.236357:0.688735:0.236357:0.688735:0.222351:0.560606:0.222351:0.009476:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.003421:0.003421:0.004738:0.004738:0.009168:0.009476:0.009476:0.009476:0.004738
61.  Radich JP, Mauro MJ. Tyrosine kinase inhibi-:@0.524259:0.250503:0.915164:0.250503:0.915164:0.236498:0.524259:0.236498:0.009476:0.009476:0.004738:0.012657:0.000000:0.010382:0.011682:0.011716:0.003421:0.011067:0.010434:0.004550:0.008244:0.008017:0.004738:0.004550:0.015719:0.011682:0.010399:0.005077:0.011203:0.004550:0.015719:0.008244:0.004738:0.004550:0.007365:0.009168:0.005080:0.011203:0.006636:0.003421:0.010434:0.011118:0.004550:0.008586:0.003421:0.010434:0.011682:0.006636:0.011118:0.004550:0.003421:0.010434:0.010434:0.003421:0.011665:0.003421:0.005679
tor treatment for newly diagnosed chronic :@0.560606:0.264649:0.919911:0.264649:0.919911:0.250644:0.560606:0.250644:0.005798:0.011203:0.005148:0.005461:0.005798:0.005077:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.005463:0.005371:0.011203:0.005148:0.005463:0.010434:0.011118:0.014214:0.003421:0.009168:0.005473:0.011716:0.003421:0.011682:0.011511:0.010434:0.011203:0.006636:0.011118:0.011716:0.005473:0.011067:0.010434:0.005075:0.011203:0.010434:0.003421:0.011067:0.004738
myeloid leukemia. :@0.560606:0.278796:0.725663:0.278796:0.725663:0.264790:0.560606:0.264790:0.016044:0.009168:0.011118:0.003421:0.011203:0.003421:0.011716:0.013701:0.003421:0.011118:0.010399:0.008586:0.011118:0.016044:0.003421:0.011682:0.004738:0.004738
Hematol Oncol Clin :@0.734626:0.278796:0.919883:0.278796:0.919883:0.264790:0.734626:0.264790:0.011682:0.011118:0.016044:0.011682:0.005798:0.011203:0.003421:0.013701:0.014864:0.010434:0.011067:0.011203:0.003421:0.013701:0.013906:0.003421:0.003421:0.010434:0.004738
North Am.:@0.560606:0.292942:0.644024:0.292942:0.644024:0.278937:0.560606:0.278937:0.012657:0.011203:0.005148:0.005798:0.010434:0.004738:0.012657:0.016044:0.004738
 2017 Aug;31(4):577-587.:@0.643990:0.292942:0.843735:0.292942:0.843735:0.278937:0.643990:0.278937:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.012657:0.010399:0.011511:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
62.  Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/:@0.524259:0.307088:0.915190:0.307088:0.915190:0.293083:0.524259:0.293083:0.009476:0.009476:0.004738:0.012657:0.000000:0.014864:0.005798:0.005798:0.004020:0.008852:0.012657:0.004738:0.004009:0.011682:0.011203:0.011716:0.003421:0.004020:0.008296:0.008518:0.004738:0.004011:0.010382:0.011203:0.011665:0.011118:0.005148:0.005798:0.004006:0.013906:0.004738:0.004020:0.013906:0.007286:0.007902:0.012657:0.005679:0.009476:0.004020:0.011682:0.010434:0.011716:0.004020:0.010126:0.012726:0.005679:0.009476:0.007475
PD-L1 blockade: new immunotherapeutic :@0.560606:0.321235:0.919923:0.321235:0.919923:0.307230:0.560606:0.307230:0.010126:0.012726:0.005679:0.007902:0.009476:0.007509:0.011665:0.003421:0.011203:0.011067:0.008586:0.011682:0.011716:0.011118:0.004738:0.007509:0.010434:0.011118:0.014214:0.007509:0.003421:0.016044:0.016044:0.010399:0.010434:0.011203:0.005798:0.010434:0.011106:0.005148:0.011682:0.011665:0.011118:0.010399:0.005798:0.003421:0.011067:0.004738
modalities  with  durable  clinical  benefit  in :@0.560606:0.335381:0.919905:0.335381:0.919905:0.321376:0.560606:0.321376:0.016044:0.011203:0.011716:0.011682:0.003421:0.003421:0.005798:0.003421:0.011118:0.006636:0.004738:0.003435:0.014214:0.003421:0.005798:0.010434:0.004738:0.003426:0.011716:0.010399:0.005148:0.011682:0.011665:0.003421:0.011118:0.004738:0.003428:0.011067:0.003421:0.003421:0.010434:0.003421:0.011067:0.011682:0.003421:0.004738:0.003438:0.011665:0.011118:0.010434:0.011118:0.004165:0.004165:0.005798:0.004738:0.003417:0.003421:0.010434:0.004738
melanoma patients. :@0.560606:0.349528:0.733531:0.349528:0.733531:0.335522:0.560606:0.335522:0.016044:0.011118:0.003421:0.011682:0.010434:0.011203:0.016044:0.011682:0.005268:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.004738:0.004738
Clin Cancer Res.:@0.734061:0.349528:0.871998:0.349528:0.871998:0.335522:0.734061:0.335522:0.013906:0.003421:0.003421:0.010434:0.005268:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.005258:0.010382:0.011118:0.006636:0.004738
 2013 :@0.871998:0.349528:0.919907:0.349528:0.919907:0.335522:0.871998:0.335522:0.005268:0.009476:0.009476:0.009476:0.009476:0.004738
Oct 1;19(19):5300-9.:@0.560606:0.363674:0.724346:0.363674:0.724346:0.349669:0.560606:0.349669:0.014864:0.011067:0.005798:0.004738:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.004738
63.  Anderson R, Rapoport BL. Immune dysreg-:@0.524259:0.377820:0.915188:0.377820:0.915188:0.363815:0.524259:0.363815:0.009476:0.009476:0.004738:0.012657:0.000000:0.012657:0.010434:0.011716:0.011118:0.005148:0.006636:0.011203:0.010434:0.006007:0.010382:0.004738:0.006021:0.010382:0.011682:0.011665:0.011203:0.011665:0.011203:0.005148:0.005798:0.006021:0.009818:0.007902:0.004738:0.006021:0.003866:0.016044:0.016044:0.010399:0.010434:0.011118:0.006021:0.011716:0.009168:0.006636:0.005085:0.011118:0.011511:0.005679
ulation in cancer patients undergoing im-:@0.560606:0.391967:0.915162:0.391967:0.915162:0.377962:0.560606:0.377962:0.010399:0.003421:0.011682:0.005798:0.003421:0.011203:0.010434:0.007047:0.003421:0.010434:0.007047:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.007047:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.007047:0.010399:0.010434:0.011716:0.011118:0.005148:0.011511:0.011203:0.003421:0.010434:0.011511:0.007047:0.003421:0.016044:0.005679
mune  checkpoint inhibitor treatment  and :@0.560606:0.406113:0.919928:0.406113:0.919928:0.392108:0.560606:0.392108:0.016044:0.010399:0.010434:0.011118:0.004738:0.002795:0.011067:0.010434:0.011118:0.011067:0.008586:0.011665:0.011203:0.003421:0.010434:0.005798:0.007543:0.003421:0.010434:0.010434:0.003421:0.011665:0.003421:0.005798:0.011203:0.005148:0.007543:0.005798:0.005077:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.004738:0.002795:0.011682:0.010434:0.011716:0.004738
potential predictive strategies for  future :@0.560606:0.420260:0.919916:0.420260:0.919916:0.406254:0.560606:0.406254:0.011665:0.011203:0.005798:0.011118:0.010434:0.005798:0.003421:0.011682:0.003421:0.011853:0.011665:0.005080:0.011118:0.011716:0.003421:0.011067:0.005798:0.003421:0.009476:0.011118:0.011853:0.006636:0.005798:0.005148:0.011682:0.005798:0.011118:0.011511:0.003421:0.011118:0.006636:0.011853:0.005371:0.011203:0.005148:0.004738:0.007105:0.005371:0.010399:0.005798:0.010399:0.005071:0.011118:0.004738
clinical practice. :@0.560606:0.434406:0.709756:0.434406:0.709756:0.420401:0.560606:0.420401:0.011067:0.003421:0.003421:0.010434:0.003421:0.011067:0.011682:0.003421:0.010776:0.011665:0.005148:0.011682:0.011067:0.005798:0.003421:0.011067:0.011118:0.004738:0.004738
Front  Oncol.:@0.715794:0.434406:0.823158:0.434406:0.823158:0.420401:0.715794:0.420401:0.008296:0.005148:0.011203:0.010434:0.005798:0.004738:0.006021:0.014864:0.010434:0.011067:0.011203:0.003421:0.004738
 2018 Mar :@0.823158:0.434406:0.919900:0.434406:0.919900:0.420401:0.823158:0.420401:0.010776:0.009476:0.009476:0.009476:0.009476:0.010776:0.015719:0.011682:0.005148:0.004738
22;8:80.:@0.560606:0.448552:0.622199:0.448552:0.622199:0.434547:0.560606:0.434547:0.009476:0.009476:0.004738:0.009476:0.004738:0.009476:0.009476:0.004738
64.  Rapoport  BL,  Vorobiof  DA,  Dreosti  LM, :@0.524259:0.462699:0.894233:0.462699:0.894233:0.448693:0.524259:0.448693:0.009476:0.009476:0.004738:0.012657:0.000000:0.010382:0.011682:0.011665:0.011203:0.011665:0.011203:0.005148:0.005798:0.004738:0.004018:0.009818:0.007902:0.004738:0.004738:0.004023:0.010281:0.011203:0.005075:0.011203:0.011665:0.003421:0.011203:0.005371:0.004738:0.004023:0.012726:0.012657:0.004738:0.004738:0.004020:0.012726:0.005082:0.011118:0.011203:0.006636:0.005798:0.003421:0.004738:0.004023:0.007902:0.015719:0.004738:0.004738
et :@0.898263:0.462699:0.919917:0.462699:0.919917:0.448693:0.898263:0.448693:0.011118:0.005798:0.004738
al:@0.560606:0.476845:0.575709:0.476845:0.575709:0.462840:0.560606:0.462840:0.011682:0.003421
. Ipilimumab  in pretreated patients with :@0.575709:0.476845:0.919921:0.476845:0.919921:0.462840:0.575709:0.462840:0.004738:0.007731:0.003866:0.011665:0.003421:0.003421:0.003421:0.016044:0.010399:0.016044:0.011682:0.011665:0.004738:0.003004:0.003421:0.010434:0.007731:0.011665:0.005080:0.011118:0.005798:0.005073:0.011118:0.011682:0.005798:0.011118:0.011716:0.007731:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.007731:0.014214:0.003421:0.005798:0.010434:0.004738
advanced malignant  melanoma:  results :@0.560606:0.490992:0.919909:0.490992:0.919909:0.476986:0.560606:0.476986:0.011682:0.011716:0.009476:0.011682:0.010434:0.011067:0.011118:0.011716:0.011939:0.016044:0.011682:0.003421:0.003421:0.011511:0.010434:0.011682:0.010434:0.005798:0.004738:0.007191:0.016044:0.011118:0.003421:0.011682:0.010434:0.011203:0.016044:0.011682:0.004738:0.004738:0.007187:0.005078:0.011118:0.006636:0.010399:0.003421:0.005798:0.006636:0.004738
of  the  South  African  expanded-access :@0.560606:0.505138:0.919902:0.505138:0.919902:0.491133:0.560606:0.491133:0.011203:0.005371:0.004738:0.008503:0.005798:0.010434:0.011118:0.004738:0.008503:0.008518:0.011203:0.010399:0.005798:0.010434:0.004738:0.008499:0.012657:0.005371:0.005148:0.003421:0.011067:0.011682:0.010434:0.004738:0.008501:0.011118:0.008210:0.011665:0.011682:0.010434:0.011716:0.011118:0.011716:0.005679:0.011682:0.011067:0.011067:0.011118:0.006636:0.006636:0.004738
program.:@0.560606:0.519284:0.637678:0.519284:0.637678:0.505279:0.560606:0.505279:0.011665:0.005080:0.011203:0.011511:0.005148:0.011682:0.016044:0.004738
  J  Glob Oncol. :@0.637661:0.519284:0.772852:0.519284:0.772852:0.505279:0.637661:0.505279:0.004738:0.003686:0.008244:0.004738:0.003684:0.014915:0.003421:0.011203:0.011665:0.008432:0.014864:0.010434:0.011067:0.011203:0.003421:0.004738:0.004738
2016 Nov  2;3(5): :@0.776532:0.519284:0.919900:0.519284:0.919900:0.505279:0.776532:0.505279:0.009476:0.009476:0.009476:0.009476:0.008432:0.012657:0.011203:0.009476:0.004738:0.003681:0.009476:0.004738:0.009476:0.006312:0.009476:0.006312:0.004752:0.004738
515-523.:@0.560606:0.533431:0.627878:0.533431:0.627878:0.519425:0.560606:0.519425:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
65.  Rapoport BL, van Eeden R, Sibaud  V, :@0.524259:0.547577:0.893866:0.547577:0.893866:0.533572:0.524259:0.533572:0.009476:0.009476:0.004738:0.012657:0.000000:0.010382:0.011682:0.011665:0.011203:0.011665:0.011203:0.005148:0.005798:0.009117:0.009818:0.007902:0.004738:0.009117:0.009476:0.011682:0.010434:0.009117:0.009168:0.011118:0.011716:0.011118:0.010434:0.009117:0.010382:0.004738:0.009117:0.008518:0.003421:0.011665:0.011682:0.010399:0.011716:0.004738:0.004391:0.010198:0.004738:0.004738
et :@0.898244:0.547577:0.919899:0.547577:0.919899:0.533572:0.898244:0.533572:0.011118:0.005798:0.004738
al.:@0.560606:0.561723:0.580447:0.561723:0.580447:0.547718:0.560606:0.547718:0.011682:0.003421:0.004738
 Care for  patients undergoing  immu-:@0.580447:0.561723:0.915159:0.561723:0.915159:0.547718:0.580447:0.547718:0.011238:0.013906:0.011682:0.005078:0.011118:0.011238:0.005371:0.011203:0.005148:0.004738:0.006491:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.011238:0.010399:0.010434:0.011716:0.011118:0.005148:0.011511:0.011203:0.003421:0.010434:0.011511:0.004738:0.006489:0.003421:0.016044:0.016044:0.010399:0.005679
notherapy. :@0.560606:0.575870:0.656733:0.575870:0.656733:0.561865:0.560606:0.561865:0.010434:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738:0.004738
Support  Care  Cancer.:@0.664720:0.575870:0.864523:0.575870:0.864523:0.561865:0.664720:0.561865:0.008518:0.010399:0.011665:0.011665:0.011203:0.005148:0.005798:0.004738:0.007988:0.013906:0.011682:0.005148:0.011118:0.004738:0.007995:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738
 2017 :@0.864523:0.575870:0.919907:0.575870:0.919907:0.561865:0.864523:0.561865:0.012743:0.009476:0.009476:0.009476:0.009476:0.004738
Oct;25(10):3017-3030.:@0.560606:0.590016:0.738560:0.590016:0.738560:0.576011:0.560606:0.576011:0.014864:0.011067:0.005798:0.004738:0.009476:0.009476:0.006312:0.009476:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738